BiologicsMD has three programs focused on bone disorders including a new bone graft substitute for use in spinal fusion, a bone growth stimulator for post-menopausal osteoporosis, and compounds for the prevention and treatment of bone metastases in metastatic breast and prostate cancer. These treatments utilize the Company’s proprietary fusion protein technology with a Binding Domain to target and retain the treatments in the bone for a localized and sustained effect, and an Active Domain to achieve a therapeutic response.